$ATNM What today's announcement really adds is not immediate revenue.
It adds evidence that management is actively executing a pan-cancer HER3 strategy in humans rather than discussing one conceptually. The RADIANZ study is enrolling multiple tumor types specifically to evaluate biodistribution, uptake, PK, and dosimetry beyond prostate cancer.
Combined with the NCI-supported GBM/basket programs testing the MDSC/checkpoint hypothesis, you now have:
Plain Text
Platform Validation Effort
#1
HER3
Platform Validation Effort
#2
MDSC / Immune
running simultaneously.
That's why, in your framework, the strategic value grows faster than the asset value. The market is no longer being asked to believe in one product. It's being asked to evaluate whether multiple platforms can work together. The biggest remaining uncertainty is still clinical validation, but today's PR arguably strengthens the platform thesis more than it changes any single-product valuation.